Morgan Stanley & Co. LLC has recently announced that it has increased stake in LAVA Therapeutics NV (NASDAQ:LVTX) by 0.98%. After grabbing 10300.0 shares, the institutional investor is now in possession of 100.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.04% having worth around $16274.0.
LAVA Therapeutics NV (LVTX) concluded trading on Thursday at a closing price of $2.23, with 43.17 million shares of worth about $96.28 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 15.54% during that period and on Thursday, January 25 the price saw a gain of about 42.95%. Currently the company’s common shares owned by public are about 26.29M shares, out of which, 12.24M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bruce Fund, Fidelity Nasdaq Composite Index F, and AXA IM World Access Vehicle – Wav are the top 3 mutual funds which are holding stakes in LAVA Therapeutics NV Bruce Fund is currently holding 0.77 million shares of worth totaling $1.22 million. The company recently came buying 0.0 shares which brought its stake up to 2.94% of the company’s outstanding shares. AXA IM World Access Vehicle – Wav, after selling 0.0 shares, have now control over 0.00% of the stake in the company. It holds 10880.0 shares of worth $0.0.
However, the stock later moved at a day high price of 2.4300, or with a gain of 42.95%. Stock saw a price change of 41.14% in past 5 days and over the past one month there was a price change of 47.68%. Year-to-date (YTD), LVTX shares are showing a performance of 41.14% which decreased to -33.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.13 but also hit the highest price of $4.00 during that period. The average intraday trading volume for LAVA Therapeutics NV shares is 36.64K. The stock is currently trading 35.39% above its 20-day simple moving average (SMA20), while that difference is up 42.56% for SMA50 and it goes to 32.03% higher than SMA200.
Morgan Stanley & Co. LLC acquired 10300.0 shares of LAVA Therapeutics NV having value of about $16274.0. Data submitted at the U.S SEC by Morgan Stanley & Co. LLC revealed that the firm now holds 100.0 shares in the company valued at close to $223.0, or have control over 0.98% stake in the company. LAVA Therapeutics NV (NASDAQ: LVTX) currently have 26.29M outstanding shares and institutions hold larger chunk of about 12.62% of that. Holding of mutual funds in the company is about 2.98% while other institutional holders and individual stake holders have control over 9.65% and — of the stake respectively.
The stock has a current market capitalization of $58.63M and its 3Y-monthly beta is at 0.13. It has posted earnings per share of -$1.92 in the same period. It has Quick Ratio of 5.20 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LVTX, volatility over the week remained 7.85% while standing at 6.81% over the month.
Analysts are in expectations that LAVA Therapeutics NV (LVTX) stock would likely to be making an EPS of -$0.44 in the current quarter, while forecast for next quarter EPS is -$0.42 and it is -$1.79 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.5 which is -$0.41 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.57 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -46.61% while it is estimated to increase by 0.55% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on October 25, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it.
